Q-omics provides the consensus-scored MIR4667 profile across patient tissues and cancer cell-line models. MIR4667 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR4667 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, MIR4667 RNA expression shows 4,197 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, UCEC, and STAD as cancer lineages where MIR4667 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4667 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4667 survival associations across molecular data types. MIR4667 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4667 RNA expression–survival associations across cancer types. High MIR4667 expression shows unfavorable associations in ACC, READ, KIRC, SKCM, LGG and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR4667 RNA expression.
This table summarizes MIR4667 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4667. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4667 shows higher tumor expression in UCEC and COAD. The UCEC box plot shows higher MIR4667 RNA expression in tumor versus normal tissue (log2 FC = +0.299, t-test p = .025).
This table shows molecular features associated with MIR4667 in patient tissues and cancer cell lines. In patient samples, MIR4667 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
